Are autologous stem cell transplants still ...
Document type :
Article dans une revue scientifique: Article de synthèse/Review paper
PMID :
Permalink :
Title :
Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? a review from the chronic malignancies working party of the ebmt
Author(s) :
Garderet, Laurent [Auteur]
Centre de Recherche Saint-Antoine [UMRS893]
Morris, Curly [Auteur]
Queen's University [Belfast] [QUB]
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Gahrton, Gösta [Auteur]
Karolinska Institutet [Stockholm]
Schonland, Stefan O. [Auteur]
University of Heidelberg, Medical Faculty
Yakoub-Agha, Ibrahim [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Centre de Recherche Saint-Antoine [UMRS893]
Morris, Curly [Auteur]
Queen's University [Belfast] [QUB]
Beksac, Meral [Auteur]
Ankara University School of Medicine [Turkey]
Gahrton, Gösta [Auteur]
Karolinska Institutet [Stockholm]
Schonland, Stefan O. [Auteur]
University of Heidelberg, Medical Faculty
Yakoub-Agha, Ibrahim [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Hayden, Patrick J. [Auteur]
Trinity College Dublin
Journal title :
Biology of blood and marrow transplantation . journal of the American Society for Blood and Marrow Transplantation
Abbreviated title :
Biol. Blood Marrow Transplant.
Publication date :
2020-05-14
ISSN :
1523-6536
Keyword(s) :
Immunotherapy
Myeloma
Autologous stem cell transplantation
CAR T cells
Myeloma
Autologous stem cell transplantation
CAR T cells
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs ...
Show more >Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel agents lead to new patient care strategies. The place of ASCT in this changing landscape will be reviewed and reassessed.Show less >
Show more >Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT) remains the standard of care for transplant-eligible patients with myeloma. However, therapies such as new immunomodulatory drugs and proteasome inhibitors and, more recently, monoclonal antibodies and chimeric antigen receptor T cells are challenging the traditional role of ASCT. Which patients benefit from ASCT? Can its use be delayed until first relapse? The field is moving rapidly as novel agents lead to new patient care strategies. The place of ASCT in this changing landscape will be reviewed and reassessed.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:48:04Z
2024-03-27T10:29:09Z
2024-03-27T10:29:09Z